Related Experiment Videos
Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention
Michael S Rafii1, Paul S Aisen2
1Alzheimer's Therapeutic Research Institute (ATRI), Keck School of Medicine, University of Southern California, 9860 Mesa Rim Road, San Diego, CA, 92121, USA. mrafii@usc.edu.
Abstract:
Despite major academic and industry efforts, Alzheimer's disease (AD) remains the only leading cause of death for which no disease-modifying treatment is available. Disappointing clinical trials over the last several years have led to a growing consensus on the need to intervene earlier in the disease process, before the onset of any clinical symptoms. However, drug development at this stage is challenging given the difficulty of assessing a therapeutic benefit in subjects who are, by definition, clinically healthy. The US FDA recently issued new draft guidance for trials in early AD, which revised the taxonomy of AD by recognizing four stages of the disease, including an expanded view of the predementia stage. These guidelines further advance regulatory support for clinical trials in earlier stages of AD. We discuss the basis for this change and the impact it may have on early-intervention AD trials as well as on stimulating the need for improved biomarkers and outcome measures that will be required for a disease-modifying drug to win approval.
Insights
Developing treatments for Alzheimer's disease (AD) requires earlier intervention. New FDA guidance supports clinical trials in predementia stages, emphasizing the need for better biomarkers to prove drug efficacy.
Area of Science:
- Neurology
- Pharmacology
- Clinical Trial Design
Background:
- Alzheimer's disease (AD) is a leading cause of death with no disease-modifying treatments.
- Past clinical trials have yielded disappointing results, highlighting the need for earlier intervention.
- Developing treatments for preclinical or predementia stages of AD is challenging due to difficulties in assessing therapeutic benefits.
Purpose of the Study:
- To discuss the implications of recent US FDA draft guidance for early Alzheimer's disease clinical trials.
- To explore the impact of revised AD staging on drug development.
- To underscore the necessity of improved biomarkers and outcome measures for early intervention trials.
Main Methods:
- Review of recent US FDA draft guidance on Alzheimer's disease clinical trials.
- Analysis of the revised taxonomy of Alzheimer's disease stages.
- Discussion of the challenges and opportunities in early-stage AD drug development.
Main Results:
- The FDA has updated its guidance, recognizing four stages of AD, including an expanded predementia stage.
- This revised taxonomy provides increased regulatory support for clinical trials in earlier phases of AD.
- The shift necessitates the development of more sensitive biomarkers and outcome measures.
Conclusions:
- New FDA guidelines encourage earlier intervention in Alzheimer's disease drug development.
- Successful development of disease-modifying treatments for AD will depend on robust biomarkers for preclinical and predementia stages.
- The evolving regulatory landscape aims to accelerate the approval of effective therapies for Alzheimer's disease.